Evaluating UCB8600s Effect on Mast Cell Activation in the Gut for IBS and Colorectal Cancer Patients

What this Trial Is About

Researchers are evaluating the effect of a new product called UCB8600 on mast cell activation in the human gut, focusing on people with Irritable Bowel Syndrome IBS and patients undergoing colorectal cancer surgery. IBS is a condition causing abdominal pain and changes in stool, with current treatments offering limited success. Mast cells release histamine when activated, which may increase nerve sensitivity and contribute to IBS symptoms. This study aims to see if UCB8600 can reduce mast cell activation in intestinal tissue, potentially leading to future treatments for IBS. The study involves collecting tissue samples from two groups colonic resection material from patients having abdominal surgery for colorectal cancer and rectal biopsies from IBS patients. Researchers will apply UCB8600 to these tissues to observe its effect on mast cell activation. The study is interventional but non-randomized and does not involve a placebo or masking. The primary measurement is the percentage of activated mast cells and the fluorescence per mast cell, assessed approximately two days after the tissue analysis. Participants provide tissue samples either during surgery or biopsy procedures. The study monitors mast cell activation using fluorescence microscopy and measures total corrected cellular fluorescence per mast cell. This evaluation occurs shortly after sample collection and treatment application. Participation involves consent, tissue sample collection, and follow-up for research measurements. The study is planned to run from August 2026 to April 2028, and participants include adults aged 18 to 65. Safety and outcomes are carefully observed, with no direct treatment administered to participants.

Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut